10‑Minute Substance‑Use‑Disorder Assessment Guidelines

Universal Screening

• The American Family Physician recommends a single‑question screen (“How many times in the past year have you used an illegal drug or a prescription medication for non‑medical reasons?”) for every patient, regardless of presentation; the question takes ≤30 seconds, yields 90‑100 % sensitivity and 74 % specificity for detecting substance‑use disorders. 1

Brief Structured Assessment Tools

Drug Abuse Screening Test‑10 (DAST‑10)

• For any positive single‑question screen, the DAST‑10 should be administered (self‑report, 2–3 minutes). It demonstrates 90‑100 % sensitivity and 77 % specificity. 1
• Interpretation of DAST‑10 scores: 0 = low risk; 1‑3 = moderate risk requiring monitoring; >3 = substance abuse or dependence. 1

Pregnancy‑Specific Screening (Women of Child‑bearing Age)

• Clinicians should assess pregnancy status and contraception in women of child‑bearing age as part of the substance‑use evaluation. 2

Adolescent Screening

• The CRAFFT tool is preferred for adolescents; it requires ~74 seconds for provider administration or ~49 seconds for computer self‑administration. 3
• Parents should be asked to leave the room to ensure confidentiality and improve response accuracy. 3
• Federal and state privacy statutes grant adolescents confidentiality for substance‑use treatment. 3

Risk Stratification & Targeted Assessment

Hazardous Use (DAST‑10 1‑3)

• Assess frequency and context of use, and inquire about legal, relational, or occupational consequences.
• Recognize that use of heroin, methamphetamine, or crack cocaine carries intrinsically high harm regardless of frequency. 1

Substance Abuse (DAST‑10 > 3 without dependence features)

• Screen for DSM‑5 criteria such as failure to meet obligations, hazardous use, legal problems, and continued use despite social or interpersonal issues. 1

Substance Dependence (DAST‑10 > 3 with dependence features)

• Rapidly evaluate for ≥3 of the following: tolerance, withdrawal, loss of control, persistent desire to quit, time spent obtaining/using, reduction of other activities, and continued use despite problems. 1

Comorbidities & Non‑Judgmental Communication

• Mental‑illness screening (depression, anxiety) is mandatory because of high co‑occurrence and impact on treatment success. (Evidence cited in the same source as the screening recommendations.) 2
• Use a neutral, matter‑of‑fact tone; avoid stigmatizing language (“addict,” “clean”). Frame substance‑use disorder as a treatable medical condition and explain that treatment is safe. 2

Laboratory & Diagnostic Considerations

• Routine urine drug testing should not be used for initial screening; reserve it for confirming a suspected diagnosis or for ongoing treatment monitoring. 1

Documentation, Intervention Intensity, and Follow‑Up

• Document the risk category (hazardous use, abuse, dependence) to guide the intensity of intervention. 1

Confidentiality & Safety

• Clinicians must maintain confidentiality and disclose information only when there is an immediate risk of harm to the patient or others. 3

All facts are derived from cited sources; strength of evidence is indicated where reported (e.g., validated tools with high sensitivity/specificity). No patient‑identifying details are included.

Screening for Substance Misuse

Initial Screening Approach

• The American Academy of Family Physicians recommends using a single-question screen asking "How many times in the past year have you used an illegal drug or used a prescription medication for nonmedical reasons?" as the initial screening tool, which demonstrates 90-100% sensitivity and 74% specificity for substance use disorders 4.
• A single-question screen "How many times in the past year have you used an illegal drug or used a prescription medication for nonmedical reasons?" can be used for rapid universal screening in primary care, with any response of 1 or more times considered a positive screen 4, 5.

Secondary Screening for Positive Results

• If the single-question screen is positive, the Drug Abuse Screening Test-10 (DAST-10) can be administered to quantify risk level, with a scoring system that stratifies patients into low risk (0 points), moderate risk (1-3 points), and substance abuse or dependence (>3 points) 4, 6.
• The DAST-10 demonstrates 90-100% sensitivity and 77% specificity for substance use disorders 4.

Risk Stratification After Positive Screen

• The American Academy of Family Physicians recommends stratifying positive screens into three categories to guide intervention intensity: hazardous use, substance abuse, and substance dependence 6, 7.
• Hazardous use is characterized by infrequent use with potential health consequences, risk of dependence, or legal repercussions, and requires brief counseling using motivational interviewing approach and ongoing assessment 6, 7.
• Substance abuse is characterized by one or more of the following within 12 months: recurrent use causing failure to fulfill major role obligations, recurrent use in physically hazardous situations, recurrent substance-related legal problems, or continued use despite persistent social/interpersonal problems, and requires brief counseling, negotiation of a plan, and close follow-up 6, 8.
• Substance dependence is characterized by three or more criteria within 12 months, including tolerance, withdrawal, loss of control, persistent desire to quit, time spent obtaining/using/recovering, reduced activities, or continued use despite problems, and requires brief counseling, referral for specialty treatment, and consideration of pharmacotherapy 8, 9.

Special Considerations for High-Risk Substances

• The American Academy of Family Physicians recognizes that not all substance use carries equal risk, with intrinsically high-risk substances such as heroin, methamphetamine, and crack cocaine associated with high risk of harm to self and others 6.

Role of Urine Drug Testing

• Routine urine drug testing is not recommended for screening purposes, but can be used selectively to support a suspected diagnosis, assess for polysubstance use, or monitor treatment response 4, 6.

Implementation in Clinical Practice

• Universal screening is justified despite insufficient evidence that screening alone improves outcomes, based on high prevalence, substantial morbidity and mortality, and proven effectiveness of early identification 10, 11, 12.
• The American Academy of Family Physicians recommends screening annually in established patients 5.
• Comorbidities such as mental illness and intimate partner violence should be assessed in patients with substance use disorders 11.